Hana Totary-Jain

Hana Totary-Jain, PhD

Assistant Professor, Molecular Pharmacology and Physiology

Assistant Professor, College of Medicine Molecular Pharmacology & Physiology

Contact Info 12901 Bruce B. Downs Blvd.
MDC8, Room 2025
Tampa FL 33612

Academic Email: totaryjainh@health.usf.edu

Academic Phone:(813) 974-6821

Education

  • PhD, Pharmacology, the Hebrew University of Jerusalem, 2005

Interdisciplinary and Emerging Signature Programs

  • Allergy, Immunology & Infectious Disease
  • Biomedical Engineering & Nanomedicine
  • Cardiovascular Sciences
  • Cellular and Molecular Biology

Research Interests

  • Our research is focused on elucidating the role of non-coding RNA in vascular diseases. We are currently working on two different areas: 1) use non-coding RNA to confer tissue specificity to novel therapeutics for vascular diseases, including coronary artery stent restenosis. 2) Study the role of microRNA in infantile hemangioma

Recent Publications

  • Canfield J & Totary-Jain H, . 40 Years of Percutaneous Coronary Intervention: History and Future Directions Journal of Personalized Medicine. 8(4) : 33
  • Totary-Jain . Modulation of LIN28B/Let-7 signaling by propranolol contributes to infantile hemangioma involution Atherosclerosis Thrombosis and Vascular Biology. , 2018.
  • Totary-Jain H, Sionov RV, Gallily R. Indomethacin sensitizes resistant transformed cells to macrophage cytotoxicity. Immunology Letters. 176: 1-7, 2016. http://www.ncbi.nlm.nih.gov/pubmed/27210423
  • Santulli G, Wronska A, Uryu K, Diacovo TG, Gao M, Marx SO, Kitajewski J, Chilton JM, Akat KM, Tuschl T, Marks AR, Totary-Jain H. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. The Journal of clinical investigation. 124(9) : 4102-14, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25133430
  • Akat KM, Moore-McGriff D, Morozov P, Brown M, Gogakos T, Correa Da Rosa J, Mihailovic A, Sauer M, Ji R, Ramarathnam A, Totary-Jain H, Williams Z, Tuschl T, Schulze PC. Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Proceedings of the National Academy of Sciences of the United States of America. 111(30) : 11151-6, 2014. http://www.ncbi.nlm.nih.gov/pubmed/25012294
  • Totary-Jain H, Sanoudou D, Ben-Dov IZ, Dautriche CN, Guarnieri P, Marx SO, Tuschl T, Marks AR. Reprogramming of the microRNA transcriptome mediates resistance to rapamycin. The Journal of biological chemistry. 288(9) : 6034-44, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23300087
  • Santulli G, Totary-Jain H. Tailoring mTOR-based therapy: molecular evidence and clinical challenges. Pharmacogenomics. 14(12) : 1517-26, 2013. http://www.ncbi.nlm.nih.gov/pubmed/24024901
  • Totary-Jain H, Marks AR. MicroRNAs and the cellular response to rapamycin: potential role in diagnosis and therapy. Cell cycle (Georgetown, Tex.). 12(6) : 861-2, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23442794
  • Totary-Jain H, Sanoudou D, Dautriche CN, Schneller H, Zambrana L, Marks AR. Rapamycin resistance is linked to defective regulation of Skp2. Cancer research. 72(7) : 1836-43, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22311674
  • Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circulation. Cardiovascular interventions. 4(1) : 104-11, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21325199
  • Shan J, Nguyen TB, Totary-Jain H, Dansky H, Marx SO, Marks AR. Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 105(48) : 19006-11, 2008. http://www.ncbi.nlm.nih.gov/pubmed/19020099
  • Totary-Jain H, Naveh-Many T, Riahi Y, Kaiser N, Eckel J, Sasson S. Calreticulin destabilizes glucose transporter-1 mRNA in vascular endothelial and smooth muscle cells under high-glucose conditions. Circulation research. 97(10) : 1001-8, 2005. http://www.ncbi.nlm.nih.gov/pubmed/16210549
  • Alpert E, Altman H, Totary H, Gruzman A, Barnea D, Barash V, Sasson S. 4-Hydroxy tempol-induced impairment of mitochondrial function and augmentation of glucose transport in vascular endothelial and smooth muscle cells. Biochemical pharmacology. 67(10) : 1985-95, 2004. http://www.ncbi.nlm.nih.gov/pubmed/15130774
  • Alpert E, Gruzman A, Totary H, Kaiser N, Reich R, Sasson S. A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: role of glucose and 12-hydroxyeicosatetraenoic acid. The Biochemical journal. 362(Pt 2) : 413-22, 2002. http://www.ncbi.nlm.nih.gov/pubmed/11853550
  • Cerasi E, Marshak S, Totary H, Melloul D. [1997 Maurice Dérot. Transcriptional regulation of the insulin gene: a step toward gene therapy of diabetes]. Journées annuelles de diabétologie de l'Hôtel-Dieu. : 299-304, 1997. http://www.ncbi.nlm.nih.gov/pubmed/9296985
  • Marshak S, Totary H, Cerasi E, Melloul D. Purification of the beta-cell glucose-sensitive factor that transactivates the insulin gene differentially in normal and transformed islet cells. Proceedings of the National Academy of Sciences of the United States of America. 93(26) : 15057-62, 1996. http://www.ncbi.nlm.nih.gov/pubmed/8986763

Positions Held

  • Associate Research Scientist (Physiology and Cellular Biophysics, Columbia University 2011 - 2013)
  • Postdoctoral Fellow (Physiology and Cellular Biophysics, Columbia University 2008 - 2011)

Awards/Honors

  • Robert W. Hobson, II, MD, Early Career Investigator Award (American Heart Association (The Council of Peripheral Vascular Disease) - 2013)
  • NIH Pathway to Independence Award (NIH/NHLBI - 2011)
  • NIH Postdoctoral Fellowship Award (NIH/NHLBI - 2008)
  • The Diabetes Research Centre of the Hebrew University (The Hebrew University of Jerusalem - 2004)
  • Israel Ministry of Science Fellowship Award (Israel Ministry of Science - 2003)
  • Israel Ministry of Science Fellowship Award (Israel Ministry of Science - 2002)